Nektar Therapeutics Surges 1910% in Three Days, $826 Million Trading Volume Ranks 92nd in Market Activity

On June 25, 2025, Nektar Therapeutics (NKTR) saw a trading volume of $826 million, ranking 92nd in the day's stock market activity. The stock surged by 19.10%, marking its third consecutive day of gains, with a cumulative increase of 242.19% over the past three days.

Nektar Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to NKTR-214 in combination with Opdivo (nivolumab) for the treatment of metastatic urothelial cancer. This designation is based on positive results from the Phase 1/2 PIVOT-02 trial, which demonstrated a 45% objective response rate in patients with metastatic urothelial cancer who had previously received platinum-based chemotherapy.

Nektar Therapeutics has also reported positive interim results from the Phase 2 portion of the PIVOT-02 trial, which evaluated NKTR-214 in combination with Opdivo in patients with metastatic urothelial cancer. The results showed that the combination therapy achieved a 45% objective response rate, with a median duration of response of 10.3 months. The safety profile of the combination therapy was consistent with the known profiles of the individual agents.

Nektar Therapeutics has entered into a collaboration with Bristol Myers Squibb to develop and commercialize NKTR-214 in combination with Opdivo for the treatment of various types of cancer. Under the terms of the agreement, Nektar will receive an upfront payment of $200 million and is eligible for potential milestone payments of up to $1.2 billion, as well as tiered royalties on future sales of the combination therapy.